PD-1 및 PD-L1 억제제 시장 규모, 점유율, 성장 분석 : 제품별, 적응증별, 유통 채널별, 지역별 - 산업 예측(2024-2031년)

Global PD-1 and PD-L1 Inhibitors Market size was valued at USD 46.8 billion in 2022 and is poised to grow from USD 55.18 billion in 2023 to USD 206.0 billion by 2031, growing at a CAGR of 17.9% during the forecast period (2024-2031).

The PD-1/PD-L1 inhibitor market has experienced transformative growth, driven by rising cancer prevalence and heightened awareness of immunotherapy. These innovative drugs target immune evasion mechanisms, successfully enabling T cells to combat various cancers, including lung, melanoma, and bladder cancers. Since the FDA's approval of pembrolizumab (Keytruda) in 2014, numerous inhibitors have entered the market, including nivolumab and atezolizumab. North America currently leads the market due to its robust healthcare infrastructure, but growth is anticipated in the Asia-Pacific region as awareness of immunotherapy rises. Key players like Merck, Roche, and Bristol-Myers Squibb are actively advancing development and forming partnerships. Nevertheless, high treatment costs and side effects could temper market expansion amidst emerging competition in personalized medicine.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pd-1 and Pd-L1 Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pd-1 and Pd-L1 Inhibitors Market Segmental Analysis

Global PD-1 and PD-L1 Inhibitors Market is segmented by product, indication, distribution channel and region. Based on product, the market is segmented into nivolumab, pembrolizumab, atezolizumab, avelumab and durvalumab. Based on indication, the market is segmented into melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck squamous cell cancer (HNSCC), bladder cancer, merkel cell carcinoma (MCC) and others. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pd-1 and Pd-L1 Inhibitors Market

The global PD-1 and PD-L1 inhibitors market is primarily driven by the escalating prevalence of cancer. With cancer positioned as the second leading cause of death worldwide, the World Health Organization projected approximately 12 million fatalities in 2022 alone. The notable effectiveness of PD-1 and PD-L1 inhibitors in treating diverse cancer types, including lung cancer, melanoma, and bladder cancer, underscores their importance in therapeutic applications. As the incidence of cancer continues to rise and the demand for efficient treatment alternatives grows, the PD-1 and PD-L1 inhibitors market is poised for significant expansion in response to these pressing healthcare needs.

Restraints in the Global Pd-1 and Pd-L1 Inhibitors Market

The global PD-1 and PD-L1 inhibitors market faces significant restraints primarily due to the high costs associated with these therapies. These inhibitors tend to be expensive, thereby restricting access for many patients, especially in developing regions. Moreover, the potential side effects-ranging from fatigue and nausea to diarrhoea-can further deter patients from opting for these advanced treatments. As a result, both healthcare providers and patients might gravitate towards more affordable alternatives like conventional chemotherapy. This situation not only imposes a financial strain on healthcare systems and insurance providers but also affects their willingness to reimburse the costs of these specialized drugs.

Market Trends of the Global Pd-1 and Pd-L1 Inhibitors Market

A significant trend shaping the global PD-1 and PD-L1 inhibitors market is the escalating emphasis on combination therapies. Recent studies indicate that integrating PD-1/PD-L1 inhibitors with other therapeutic modalities, such as chemotherapy or alternative immunotherapies, can markedly enhance treatment efficacy and mitigate the potential for resistance development. Major market players are channeling substantial resources into the formulation and clinical testing of innovative combination regimens, reflecting a collective effort to optimize patient outcomes. This trend is poised to gain momentum in the ensuing years as the medical community endeavors to transcend the constraints associated with PD-1/PD-L1 inhibitors when used as standalone treatments.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global PD-1 and PD-L1 Inhibitors Market Size by Product & CAGR (2024-2031)

• Market Overview
• Nivolumab
• Pembrolizumab
• Atezolizumab
• Avelumab
• Durvalumab

Global PD-1 and PD-L1 Inhibitors Market Size by Indication & CAGR (2024-2031)

• Market Overview
• Melanoma
• Non-Small Cell Lung Cancer (NSCLC)
• Renal Cell Carcinoma (RCC)
• Head and Neck Squamous Cell Cancer (HNSCC)
• Bladder Cancer
• Merkel Cell Carcinoma (MCC)
• Others

Global PD-1 and PD-L1 Inhibitors Market Size by Distribution Channel & CAGR (2024-2031)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global PD-1 and PD-L1 Inhibitors Market Size & CAGR (2024-2031)

• North America (Product, Indication, Distribution Channel)
  • USA
  • Canada
• Europe (Product, Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, By Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Akeso Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alphamab Oncology
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca Plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline Plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Innovent Biologics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck and Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations